A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Alterome Therapeutics, Inc.
Revolution Medicines, Inc.
Fate Therapeutics
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center